Skip to content

Lovastatin

    DEA Class; Rx

    Common Brand Names; Mevacor, Altoprev

    • Lipid-Lowering Agents, Statins; 
    • HMG-CoA Reductase Inhibitors

    Oral antilipemic agent; HMG-CoA reductase inhibitor; used for hypercholesterolemia.

     

    Indicated

    For the treatment of hypercholesterolemia, including hyperlipidemia, hyperlipoproteinemia, or hypertriglyceridemia, as an adjunct to dietary control.

    For myocardial infarction prophylaxis (primary prevention).
    For myocardial infarction prophylaxis (primary prevention).
    For slowing the progression of atherosclerosis in patients with carotid artery disease (i.e., stroke prophylaxis).

    Hypersensitivity to lovastatin or other components

    Active liver disease, or unexplained elevated transaminases

    Concomitant administration with strong CYP3A4 inhibitors (eg, itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, cobicistat, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, and nefazodone)

    CPK elevation (11%)

    Flatulence (4-5%)

    Abdominal pain (2-3%)

    Constipation (2-3%)

    Diarrhea (2-3%)

    Myalgia (2-3%)

    Nausea (2-3%)

    Dyspepsia (1-2%)

    Weakness (1-2%)

    Blurred vision (0.8-1%)

    Rash (0.8-1%)

    Muscle cramps (0.6-1%)

    Dizziness (0.5-1%)

    <1%

    Dermatomyositis

    Increased LFTs

    Hepatotoxicity

    Myopathy

    Rhabdomyolysis

    Interstitial lung disease

    Nonserious and reversible cognitive side effects may occur

    Avoid coadministration with cyclosporine or gemfibrozil; caution with other fibrates or lipid-lowering doses of niacin (≥1 g/day) because of increased risk for myopathy

    Use caution in heavy alcohol use, history of liver disease, or renal failure

    Obtain baseline liver enzyme tests before initiating and then periodically thereafter

    Increases in HbA1c and fasting serum glucose levels reported

    HMG-CoA reductase inhibitor shown to reduce plasma testosterone response to HCG; effects of HMG-CoA reductase inhibitors on male fertility not studied in adequate numbers of male patients

    Effects of therapy, if any, on pituitary-gonadal axis in premenopausal women are unknown; patients who develop clinical evidence of endocrine dysfunction should be evaluated appropriately

    Use caution if an HMG-CoA reductase inhibitor or other agent used to lower cholesterol levels is administered to patients also receiving other drugs (e.g., spironolactone, cimetidine) that may decrease levels or activity of endogenous steroid hormones

    Risk of myopathy increased by coadministration of CYP3A4 inhibitors or other drugs that cause myopathy

    Owing to HMG-CoA reductase inhibitors decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, fetal harm may occur when administered to pregnant females

    There is no available information on effects of drug on breastfed infant or on milk production

    Unknown whether is present in human milk; it has been shown that drugs in this class pass into human milk and atorvastatin is present in rat milk

    Not recommended during treatment

    Adults

    80 mg/day PO immediate-release tablets (e.g., Mevacor); 60 mg/day PO extended-release tablets (Altoprev). Max 20 mg/day PO immediate-release or extended-release lovastatin if taking fibrates, niacin, danazol, or cyclosporine; max 40 mg/day PO immediate-release lovastatin if taking amiodarone or verapamil; max 20 mg/day PO extended-release lovastatin if taking amiodarone or verapamil.

    Geriatric

    80 mg/day PO immediate-release tablets (e.g., Mevacor); 60 mg/day PO extended-release tablets (Altoprev). Max 20 mg/day PO immediate-release or extended-release lovastatin if taking fibrates, niacin, danazol, or cyclosporine; max 40 mg/day PO immediate-release lovastatin if taking amiodarone or verapamil; max 20 mg/day PO extended-release lovastatin if taking amiodarone or verapamil.

    Adolescents

    40 mg/day PO immediate-release tablets (e.g., Mevacor). Safety and efficacy have not been established for extended-release tablets (e.g., Altoprev).

    Children

    10 years and older: 40 mg/day PO immediate-release tablets (e.g., Mevacor). Safety and efficacy have not been established for extended-release tablets (e.g., Altoprev).
    Less than 10 years: Safety and efficacy have not been established.

    Lovastatin

    tablets, extended-release

    • 20mg
    • 40mg
    • 60mg

    tablets

    • 10mg
    • 20mg
    • 40mg